Fig. 6: YAP nanobody bioPROTAC arrests tumor growth in vivo.
From: Targeted degradation of endogenous YAP by nanobody bioPROTAC inhibits tumor progression
A–C E8-2RNF4 inhibits tumor growth in multiple xenograft models. MDA-MB-231 (C3-2RNF4 or E8-2RNF4), MSTO-211H (E8-2RNF4), and IM95 (E8-2RNF4) cells were subcutaneously implanted into immunodeficient mice to establish multiple xenograft models. Once average tumor size reached ~100 mm3, the animals were randomly grouped and given drinking water with/without doxycycline (DOX, 0.5 mg/ml). n = 7 (MDA-MB-231 and MSTO-211H), n = 8 (IM95). Data are mean ± SEM, two-way ANOVA with Tukey’s test for multiple comparisons, “ns” represents no significant difference. D–F E8-2RNF4 prolongs the survival of animals in the xenografted models shown in (A–C). Two-sided Mantel–Cox log-rank test with Holm-Sidak correction for multiple comparisons, “ns” represents no significant difference. G Tumor growth curves of the 92.1 (E8-2RNF4) xenograft model. 92.1 (E8-2RNF4) cells were subcutaneously implanted into BALB/c nude mice. Once average tumor size reached ~100 mm3, the animals were randomly grouped and given drinking water with/without DOX (0.5 mg/ml) (n = 8 biological replicates, mean ± SEM, two-way ANOVA). H Images and weights of the isolated tumor tissues from 92.1 tumor-bearing mice after euthanasia (n = 8 biological replicates, mean ± SEM, two-sided Student’s t-test). I Representative immunohistochemical images for HA, YAP and Ki-67 expression in tumors from the 92.1 (E8-2RNF4) xenograft model. Quantification of YAP and Ki-67 expression is shown on the right. The DOX-treated group exhibited a notable increase in HA expression and a concurrent decrease in both YAP and Ki-67 expression (n = 3 biological replicates, mean ± SEM, two-sided Student’s t-test). Source data are provided as a Source Data file.
